Skip to main content

SUPERNUS PHARMACEUTICALS INC

For the period ended Sep 30, 2024. Filed Nov 4, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 4, 2024

SUPN$28.75+4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Changes in Stockholders' Equity

Nine Months Ended September 30, 2024 and 2023

(unaudited, in thousands, except share data)

j · Common Stock · Additional Paid-in Capital · Accumulated OtherComprehensiveEarnings (Loss) · RetainedEarnings · TotalStockholders’Equity
Shares · Amount
Balance, December 31, 202354,723,356$55$439,493$(593)$482,561$921,516
Share-based compensation expense related to employee stock purchase plan and share-based awards——5,897——5,897
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld241,960—1,570——1,570
Net earnings————124124
Unrealized gain on marketable securities, net of tax———59—59
Balance, March 31, 202454,965,31655446,960(534)482,685929,166
Share-based compensation expense related to employee stock purchase plan and share-based awards——6,552——6,552
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld80,733—1,658——1,658
Net earnings————19,91619,916
Unrealized gain on marketable securities, net of tax———162—162
Balance, June 30, 202455,046,04955455,170(372)502,601957,454
Share-based compensation expense related to employee stock purchase plan and share-based awards——7,674——7,674
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld173,224—3,075——3,075
Net earnings————38,49738,497
Unrealized gain on marketable securities, net of tax———450—450
Balance, September 30, 202455,219,273$55$465,919$78$541,098$1,007,150

Condensed Consolidated Statements of Changes in Stockholders’ Equity

Nine Months Ended September 30, 2024 and 2023

(unaudited, in thousands, except share data)

Common Stock · Additional Paid-in Capital · Accumulated OtherComprehensiveEarnings (Loss) · RetainedEarnings · TotalStockholders’Equity
Shares · Amount
Balance, December 31, 202254,253,796$54$408,115$(3,210)$481,245$886,204
Share-based compensation expense related to employee stock purchase plan and share-based awards——6,306——6,306
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld216,826—1,811——1,811
Net earnings————16,94816,948
Unrealized gain on marketable securities, net of tax———881—881
Balance, March 31, 202354,470,62254416,232(2,329)498,193912,150
Share-based compensation expense related to employee stock purchase plan and share-based awards——6,088——6,088
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld122,27911,946——1,947
Net loss————(831)(831)
Unrealized gain on marketable securities, net of tax———554—554
Balance, June 30, 202354,592,90155424,266(1,775)497,362919,908
Share-based compensation expense related to employee stock purchase plan and share-based awards——7,920——7,920
Issuance of common stock related to employee stock purchase plan and share-based awards, net of taxes withheld37,857—(230)——(230)
Net loss————(15,976)(15,976)
Unrealized gain on marketable securities, net of tax———569—569
Balance, September 30, 202354,630,758$55$431,956$(1,206)$481,386$912,191
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.